All In Biotech

Drug Trial Radar · NCT06070051

Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy

A Phase 1b Multi-Center, Open-Label, Dose-Escalation, Prime And Boost Vaccination Evaluation of VRON-0200 Using Two Chimpanzee Adenoviral Vectors in Adult Participants With Chronic HBV Infection Who Are Currently Receiving HBV Nucleos(t)Ide Reverse Transcriptase Inhibitors

Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

35

Actual

Start

Sep 26, 2023

Primary completion

Mar 31, 2026

Study completion Mar 31, 2026

Sponsor

Lead sponsor
Virion TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Vir Biotechnology, Inc.
First posted
Oct 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 1b clinical study is a multi-center, open-label, dose escalation, prime only, and prime plus boost therapeutic vaccination study of 2 distinct chimpanzee adenoviral vectors (AdC6 and AdC7), containing parts of hepatitis B virus (HBV) core and polymerase antigens fused within glycoprotein D in a cohort of chronic hepatitis B (CHB)-infected adult participants who are currently receiving entecavir, tenofovir (tenofovir alafenamide fumarate or tenofovir disoproxil fumarate), or lamivudine, with documented HBV viral load suppression for at least 12 months. Approximately 24 participants will be enrolled in Group 1 and randomized to Cohort 1a or Cohort 1b. Those assigned to Cohort 1a will receive a low dose prime therapeutic vaccination of vector AdC7 on Day 1, followed by a booster vaccination on Day 91 using vector AdC6. Those assigned to Cohort 1b will receive a low dose prime therapeutic vaccination of vector AdC6 on Day 1, and will not receive a booster vaccination. Group 2 will then enroll approximately 24 participants randomized to Cohort 2a or Cohort 2b. Those assigned to Cohort 2a will receive a high dose prime therapeutic vaccination of vector AdC7 on Day 1, followed by a booster vaccination on Day 91 using vector AdC6. Those assigned to Cohort 2b will receive a high dose prime therapeutic vaccination of vector AdC6 on Day 1, and will not receive a booster vaccination. Group 3 will enroll approximately 8 participants randomized into Cohort 3a or Cohort 3b. Cohort 3a will receive the high dose prime VRON-0200 vaccination of vector AdC7 on Day 1, followed by doses of VIR-2218 plus VIR-3434 on Days 28, 56, 84, 112, 140 and 168, and then a booster using a high dose VRON-0200 vaccination of vector AdC6 on Day 196. Cohort 3b will receive the same high dose prime VRON-0200 vaccination of vector AdC7 followed by 6 doses of VIR-2218 plus VIR-3434 at the same timepoints as Cohort 3a, but will not receive the booster dose on Day 196. VRON-0200 vaccine doses will be administered by intramuscular (IM) injection. VIR-2218 and VIR-3434 will be administered subcutaneously. All study participants will be followed for a total of 1 year post-prime vaccination.

Conditions

  • Chronic Hepatitis B

Interventions

  • VRON-0200-AdC6Biological

    VRON-0200 chimpanzee adenovirus serotype 6 vaccine vector

  • VRON-0200-AdC7Biological

    VRON-0200 chimpanzee adenovirus serotype 7 vaccine vector

  • VIR-2218Drug

    VIR-2218 given by subcutaneous injection

  • VIR-3434Drug

    VIR-3434 given by subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment Emergent Adverse EventsTime frame: 28 days
  2. Grade 3 Adverse EventsTime frame: 28 days
  3. Clinically Significant Changes in Lab ValuesTime frame: 28 days
  4. Serious Adverse EventsTime frame: 6 months
  5. Medically Attended Adverse EventsTime frame: 6 months

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Chinese University of Hong Kong

    Hong Kong, Hong Kong

  • Aotearoa Clinical Trials, Middlemore Hospital

    Auckland, New Zealand

  • Auckland City Hospital

    Auckland, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.